What Is GnRH? Benefits, Research & Safety

The existence of a hypothalamic factor controlling pituitary gonadotropin release was hypothesised in the 1950s by Geoffrey Harris. The isolation and characterisation of GnRH was achieved independently by Andrew Schally and Roger Guillemin, who shared the 1977 Nobel Prize in Physiology or Medicine for this work. Schally's group determined the decapeptide structure of GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) in 1971. This was a landmark achievement requiring purification from hundreds of thousands of pig hypothalami. The discovery that continuous GnRH administration paradoxically suppressed reproductive hormones (rather than continuously stimulating them) was pivotal. This led to development of GnRH agonist analogues with enhanced potency and duration for therapeutic suppression of sex hormone production. GnRH antagonists were developed subsequently, offering the advantage of immediate suppression without the initial "flare" effect seen with agonists. First-generation antagonists had formulation issues, but newer compounds became clinically successful. Today, GnRH analogues represent a multi-billion-dollar pharmaceutical class with applications across oncology, reproductive medicine, and endocrinology.